GlassScriptPhysician profile
Peter J Bellafiore
NPI 1881753135
$273,957.40
in general payments reported to CMS, 2019-2025
68 companies · $2,086 in 2025
The $2,086 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $95K · 2020: $68K · 2021: $43K · 2022: $44K · 2023: $16K · 2024: $6,450 · 2025: $2,086.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $15K · Food and Beverage: $9,560 · Education: $84.10 · Travel and Lodging: $46.54.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $14,900.00 |
| Food and Beverage | $9,559.70 |
| Education | $84.10 |
| Travel and Lodging | $46.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acadia Pharmaceuticals INC | $51,641.67 | 2019-2025 | Nuplazid, Daybue |
| Lilly USA, LLC | $51,212.36 | 2019-2025 | Emgality, Amyvid, Kisunla |
| Abbvie INC. | $44,079.01 | 2021-2025 | Ubrelvy, Qulipta, Botox |
| Amgen INC. | $36,446.53 | 2019-2025 | Uplizna, Aimovig |
| Eisai INC. | $26,957.89 | 2019-2025 | |
| Acorda Therapeutics, INC | $16,085.13 | 2019-2023 | Inbrija |
| Allergan, INC. | $12,539.30 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $7,764.02 | 2019-2025 | Ajovy, Austedo Xr, Austedo Xr |
| Biohaven Pharmaceuticals, INC. | $6,916.19 | 2020-2021 | |
| Emd Serono, INC. | $2,774.92 | 2019-2025 | Mavenclad, Mavenclad |
| Sunovion Pharmaceuticals INC. | $2,762.18 | 2019-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $2,112.55 | 2022 | |
| Novartis Pharmaceuticals Corporation | $1,122.70 | 2019-2024 | |
| Lundbeck LLC | $897.63 | 2020-2024 | Vyepti, Rexulti |
| Ucb, INC. | $792.69 | 2019-2025 | Briviact, Nayzilam, Fintepla |
Show all 68 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Bellafiore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.